Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUILD-3 open-label extension of bosentan in idiopathic pulmonary fibrosis
NL-OMON32143Phase 3Not yet recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bosentan in idiopathic pulmonary fibrosis (IPF), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Adverse events leading to premature discontinuation, Treatment-emergent serious adverse events and 1 more. Planned start Aug 2008; status: not yet recruiting.
02
Drugs
bosentan
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON32143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32143.